New Option in NSCLC With IL-15 Agonist Plus Immune Checkpoint Inhibition

The combination of nivolumab with an interleukin-15 agonist was well tolerated with no dose-limiting toxicities in patients with metastatic non –small-cell lung cancer.

Source: CancerNetwork - April 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news